当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Anas Almoghrabi, Estefania Flores, Obaie Mzaik, Chimezie Mbachi, Bashar Attar and Melchor Demetria
A substantial proportion of patients with Crohn’s Disease (CD) do not respond to the currently available medications with potential long-term consequences. Consequently, alternative safer therapies are being studied, such as Fecal Microbiota Transplantation (FMT). The Food and Drug Administration (FDA) approved the use of FMT for recurrent Clostridium difficile (C. diff) but has tighter restrictions for Inflammatory Bowel Disease (IBD). Those patients can only get a fecal transplant in a medical setting if they are participating in a clinical trial. A handful of case reports have shown the effectiveness of self-administered home fecal transplant in recurrent C. difficile, and the efficacy of FMT, under monitored environment, in refractory CD unresponsive to current conventional therapy. However, no reported cases showing the efficacy of self-administered home fecal transplant in patients with fistulizing CD. This is the first case report showing the efficacy of self-administered home fecal transplant as a single agent in the management of Crohn’s pancolitis with perianal fistulae.